2022
Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney International Reports 2022, 7: 1939-1950. PMID: 36090489, PMCID: PMC9458993, DOI: 10.1016/j.ekir.2022.06.005.Peer-Reviewed Original ResearchChronic kidney diseaseEnd-stage kidney diseaseSevere kidney dysfunctionKidney diseaseKidney dysfunctionAdvanced kidney diseaseOptimal clinical careCancer drug trialsNumber of patientsNarrow therapeutic indexInitial clinical studiesKidney replacement treatmentPreregistration studiesKidney functionCancer careReplacement treatmentCancer trialsClinical trialsEffective dosingClinical studiesTreatment decisionsDrug trialsBeneficial drugsClinical carePatientsImaging Modalities for Acute Tubulointerstitial Nephritis
Baker M, Perazella M. Imaging Modalities for Acute Tubulointerstitial Nephritis. 2022, 257-266. DOI: 10.1007/978-3-030-93438-5_20.ChaptersAcute tubulointerstitial nephritisTubulointerstitial nephritisAcute kidney injury diagnosisNonspecific constitutional symptomsChronic kidney diseaseImaging modalitiesCurrent imaging modalitiesEmission Tomography ImagingPositron emission tomography (PET) imagingNon-invasive diagnosisConstitutional symptomsFlank painMost patientsKidney diseaseKidney failureCase reportInjury diagnosisRadiographic cluesClinical dataCommon causeGallium uptakeCharacteristic signsSymptomsDiagnosisTomography imaging
2021
The Crystalline Nephropathies
Perazella MA, Herlitz LC. The Crystalline Nephropathies. Kidney International Reports 2021, 6: 2942-2957. PMID: 34901567, PMCID: PMC8640557, DOI: 10.1016/j.ekir.2021.09.003.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseKidney injuryCrystalline nephropathyKidney diseaseCrystal depositionFurther kidney injuryIntrarenal crystal depositionUrinary sediment findingsUrine sediment examinationTubular obstructionHistologic findingsPathologic aspectsNephropathyClinical standpointInjuryTubular luminaSediment examinationFluid physiologyIdentification of crystalsCliniciansDiseaseIndirect cytotoxicityBiopsyInflammationPARP inhibitors and the Kidney
Deshpande P, Perazella M, Jhaveri K. PARP inhibitors and the Kidney. Journal Of Onco-Nephrology 2021, 5: 42-47. DOI: 10.1177/2399369320987090.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseIschemic acute kidney injuryEnd-stage kidney diseaseKidney diseaseSepsis-related acute kidney injuryAdvanced chronic kidney diseasePARP inhibitorsPoly (ADP-ribose) polymeraseIncrease serum creatinineUse of PARPisBreast cancer gene mutationsStage kidney diseaseAnti-cancer effectsCancer gene mutationsSafe dosingKidney injurySerum creatinineKidney functionKidney effectsClinical trialsLong-term effectsAnimal modelsCellular necrosisPARPis
2020
Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 298: 202903. PMID: 33170103, DOI: 10.1148/radiol.2020202903.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaSimultaneous joint publicationKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskUse of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine 2020, 3: 142-150. PMID: 33604544, PMCID: PMC7873723, DOI: 10.1016/j.xkme.2020.10.001.Peer-Reviewed Original ResearchNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskFibrosisOnconephrology: The intersections between the kidney and cancer
Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA A Cancer Journal For Clinicians 2020, 71: 47-77. PMID: 32853404, DOI: 10.3322/caac.21636.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseDrug-induced nephrotoxicityKidney diseaseElectrolyte disordersAcute kidney injuryStem cell transplantationParaneoplastic glomerulonephritisKidney injuryCell transplantationTherapeutic regimensCollaborative careCancerDiseasePatientsOnconephrologyNew subspecialtySpecific training programsNephrotoxicityDisordersTraining programGlomerulonephritisRegimensNephrologistsTransplantationOncologistsIn Reply to ‘Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus’
Perazella MA, Weinreb JC, Davenport MS. In Reply to ‘Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus’. Kidney Medicine 2020, 2: 501. PMID: 32775994, PMCID: PMC7406849, DOI: 10.1016/j.xkme.2020.06.002.Peer-Reviewed Original ResearchNSAIDs in CKD: Are They Safe?
Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? American Journal Of Kidney Diseases 2020, 76: 546-557. PMID: 32479922, DOI: 10.1053/j.ajkd.2020.03.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsChronic kidney diseaseGlomerular filtration rateFiltration rateRisk factorsHigh pain burdenAcute kidney injuryManagement of painAnti-inflammatory drugsCKD populationNSAID useKidney injuryPain burdenPain controlHeart failureComorbid conditionsElectrolyte derangementsKidney diseaseSafety dataDrug effectsPatientsIndividualized basisDrug metabolismProgressive lossCautious useNomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020, 97: 1117-1129. PMID: 32409237, DOI: 10.1016/j.kint.2020.02.010.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseGlomerular filtration rateKidney diseaseKidney functionKDIGO definitionConsensus conferenceSeverity of CKDEnd-stage kidney diseaseAcute kidney diseaseAbsence of symptomsGlobal Outcomes (KDIGO) Consensus ConferenceKDIGO guidelinesKidney injuryKidney failureKidney measuresFiltration rateWorldwide burdenGlobal outcomeKidney structureDiseaseHealth communitySeverityFollowing recommendationsMore effective communicationSGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressureThe kidney–cancer connection continues to grow
Perazella M. The kidney–cancer connection continues to grow. Journal Of Onco-Nephrology 2020, 4: 26-27. DOI: 10.1177/2399369320916474.Peer-Reviewed Original ResearchUse of Intravenous Iodinated Contrast Media in Patients With Kidney Disease Consensus Statements from the American College of Radiology and the National Kidney Foundation
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine 2020, 2: 85-93. PMID: 33015613, PMCID: PMC7525144, DOI: 10.1016/j.xkme.2020.01.001.Peer-Reviewed Original ResearchAcute kidney injuryGlomerular filtration rateContrast mediumFiltration rateContrast-associated acute kidney injuryContrast-induced acute kidney injuryIntravenous normal salineReduced kidney functionSevere kidney diseaseNational Kidney FoundationIodinated Contrast MediaHigh-risk circumstancesCI-AKIKidney injuryMaintenance dialysisKidney functionKidney diseaseOrdering clinicianNormal salineConsensus statementKidney FoundationTreatment responseAmerican CollegePatientsControl groupUse of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 294: 192094. PMID: 31961246, DOI: 10.1148/radiol.2019192094.Peer-Reviewed Original ResearchConceptsAcute kidney injuryGlomerular filtration rateContrast mediumKidney diseaseFiltration rateContrast-associated acute kidney injuryContrast-induced acute kidney injuryIntravenous normal salineReduced kidney functionSevere kidney diseaseNational Kidney FoundationIodinated Contrast MediaHigh-risk circumstancesSimultaneous joint publicationCI-AKIKidney injuryMaintenance dialysisKidney functionOrdering clinicianNormal salineConsensus statementKidney FoundationTreatment responseAmerican CollegePatients18 Adverse kidney effects of immunotherapies
SALY D, PERAZELLA M. 18 Adverse kidney effects of immunotherapies. 2020, 166-182.e3. DOI: 10.1016/b978-0-323-54945-5.00027-8.Peer-Reviewed Original ResearchKidney diseaseDrug-induced kidney diseaseHigh-dose interleukin-2B-cell acute lymphoblastic leukemiaChimeric antigen receptor T cellsAntigen receptor T cellsAdverse kidney effectsImmune checkpoint inhibitorsChronic kidney diseaseChronic kidney injuryNumber of medicationsReceptor T cellsAcute lymphoblastic leukemiaConventional chemotherapeutic drugsAcid-base disturbancesOlder immunotherapiesCheckpoint inhibitorsKidney injuryNovel immunotherapiesNew immunotherapiesCancer patientsKidney effectsKidney lesionsLymphoblastic leukemiaImmune cells
2019
Evolution of the kidney–cancer connection
Perazella M, Workeneh B, Chen S. Evolution of the kidney–cancer connection. Journal Of Onco-Nephrology 2019, 3: 88-91. DOI: 10.1177/2399369319841616.Peer-Reviewed Original ResearchOnco-NephrologyKidney diseaseCare medicineMD Anderson Cancer CenterPalliative care medicineAnderson Cancer CenterCritical care medicineCancer CenterClinical pharmacologyClinical practiceAreas of medicineCancerDiseaseSpecialty groupsPatientsClinical medicineHighlights sectionMedicineTherapyNephrologyOncologyHematologyUrologyPharmacology
2018
The adverse kidney effects of cancer immunotherapies
Saly D, Perazella M. The adverse kidney effects of cancer immunotherapies. Journal Of Onco-Nephrology 2018, 2: 56-68. DOI: 10.1177/2399369318808806.Peer-Reviewed Original ResearchChronic kidney diseaseKidney diseaseCancer immunotherapyInterleukin-2High-dose interleukin-2Chimeric antigen receptor T cellsAntigen receptor T cellsMore effective treatment optionsAdverse kidney effectsImmune checkpoint inhibitorsAcute kidney diseaseEffective treatment optionReceptor T cellsCase-based reviewCancer therapyGroup of drugsNew cancer immunotherapiesCancer treatment armamentariumConventional chemotherapeutic drugsList of cancersOlder immunotherapiesCheckpoint inhibitorsTreatment armamentariumNew immunotherapiesTreatment options35 Kidney Disease Caused by Therapeutic Agents
Perazella M, Shirali A. 35 Kidney Disease Caused by Therapeutic Agents. 2018, 334-344. DOI: 10.1016/b978-0-323-47794-9.00035-4.BooksKidney diseaseTherapeutic agentsDrug-induced renal toxicityProteinuria/nephrotic syndromeFrequent adverse consequencesChronic kidney diseaseChronic kidney injuryDrugs of abuseSubgroup of individualsDrug nephrotoxicityKidney injuryMost medicationsNephrotoxic drugsTubular dysfunctionNephrotic syndromeRenal toxicityDrug therapyRisk factorsTherapeutic medicationsRenal syndromeAppropriate careMedicationsNephrotoxicitySyndromeAdverse consequences
2017
New Horizons in Nephrology: Update in Onco-Nephrology
Perazella M. New Horizons in Nephrology: Update in Onco-Nephrology. Journal Of Onco-Nephrology 2017, 1: 147-150. DOI: 10.5301/jo-n.5000033.Peer-Reviewed Original ResearchGrowth of the Kidney–Cancer Connection
Perazella M. Growth of the Kidney–Cancer Connection. Journal Of Onco-Nephrology 2017, 1: 71-73. DOI: 10.5301/jo-n.5000015.Peer-Reviewed Original Research